Recent Findings for Anti-Metastatic Potential of Heparin

Green D , Hull RD , Brant R , et al. Lower mortality in cancer patients treated with low molecular weight versus standard heparin.Lancet 1992;339:1476-1476.

Siragusa S , Cosmi B , Piovella F , et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med 1996;100:269-269.

Gould MK , Dembitzer AD , Doyle RL , et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-800.

Altinbas M , Coskun HS , Er O , et al. A randomized clinical trial of combination chemotherapy with and without low molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-1266.

Lee AYY , Rickles FR , Julian JA , et al. A randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2123.

Klerk CPW , Smorenburg SM , Otten HM , et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2130.

Lemoine NR . Antithrombotic therapy in cancer. J Clin Oncol 2005;23:2119-2119.

Balkwill F . Cancer and chemokine network. Nat Rev Cancer 2004;4:540-540.

Muller A , Homey B , Soto, H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-50.

Cahalon L , Lider O , Schor H , et al. Heparin disaccharides inhibit tumor necrosis factor-α production by macrophages and arrest immune inflammation in rodents. Int Immunol 1997;9:1517-1517.

Hecht I , Hershkoviz R , Shivtiel S , et al. Heparin-disaccharide affects T cells: Inhibition of NF-kappaB activation, cell migration, and modulation of intracellular signaling. J Leukoc Biol 2004;75:1139-1139.

Harvey JR , Mellor P , Kirby JA , et al. Preventing breast cancer metastasis—heparins as inhibitors of chemokine function. Proc Am Assoc Cancer Res 2005;46:abstract 5207-5207.

Veldkamp CT , Peterson FC , Pelzek AJ , Volkman BF . The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci 2005;14:1071-1071.